Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Pharmasset, a clinical-stage pharmaceutical company engaged in discovering, developing, and commercializing novel drugs to treat viral infections, has initiated a Phase 2b Atomic Trial evaluating PSI-7977 as a treatment for chronic hepatitis C (HCV).
Subscribe to our email newsletter
Pharmasset will assess PSI-7977 400mg QD with pegylated interferon and ribavirin in patients with HCV genotype 1, 4, 5 or 6 who have not been treated previously.
The company is planning to recruit around 300 patients in the trial.
The primary endpoint of the trial will be the safety and tolerability of PSI-7977 in combination with peginterferon and ribavirin over 12 or 24 weeks.